Salman Fazal, MD

In this concluding segment, the panel reflects on the evolving landscape of treatment for myeloid malignancies, including high-risk MDS and CML, with a focus on oral HMAs. Dr. Fazal emphasizes the importance of clinical trial participation, noting that although some combination therapies may not show overall superiority, subsets of patients demonstrate meaningful benefit, highlighting the need for ongoing research and novel therapeutic strategies.

This segment focuses on practical strategies for managing high-risk CML, particularly in patients with proliferative and cytopenic symptoms. The discussion begins with balancing symptomatic management, such as fatigue, early satiety, splenomegaly, anemia, and thrombocytopenia, alongside disease-directed therapy.

The panel discusses the case of a 67-year-old female patient diagnosed with high-risk chronic myelomonocytic leukemia (CML-1) who presents with intermediate risk scores and abnormal blood counts, including elevated white blood cells, mild thrombocytopenia, and anemia.

This segment continues the discussion of high-risk MDS management, focusing on how clinicians define failure of HMAs and determine next steps in therapy, particularly in patients with TP53 mutations.

This case-based discussion illustrates the practical management of a 72-year-old patient with high-risk MDS and TP53 mutation.

This segment explores the critical role of patient support programs, insurance navigation, and balancing the convenience of oral HMAs with ongoing clinical oversight.

Explore the practical challenges of using oral hypomethylating agents, focusing on safety, access, and effective patient management strategies.

Explore the differences between bispecific antibodies and CAR T-cell therapy, highlighting their unique benefits and administration processes.

Explore the differences between bispecific antibodies and CAR T-cell therapy, highlighting their unique benefits and administration processes in cancer treatment.

Explore the latest advancements in oral hypomethylating agents for MDS and CMML, emphasizing their efficacy, patient convenience, and treatment strategies.

Panelists discuss how unmet needs and future directions for GPRC5D bispecific therapy include improving accessibility, managing long-term safety, and exploring combination strategies to enhance treatment efficacy.

Panelists discuss how the evolution of GPRC5D-targeted therapies is expected to shape future treatment approaches for relapsed/refractory multiple myeloma in community practices by offering more personalized options and improving patient outcomes.

Panelists discuss how key areas for improvement in the application of GPRC5D-targeted therapies in real-world settings include optimizing patient selection, addressing logistical challenges, and enhancing adverse event management.

Panelists discuss how additional resources such as enhanced staff training, financial support, and improved patient education could benefit the implementation of bispecific therapies in community settings.

Panelists discuss how the use of GPRC5D-targeted therapies impacts healthcare resource utilization in the community setting, including potential changes in hospitalizations, outpatient visits, and supportive care needs.

Panelists discuss how logistical barriers like drug access, insurance coverage, and managing infusion logistics have posed challenges in the implementation of GPRC5D-targeted therapies in community practice.

Panelists discuss how community practices establish protocols and processes for ongoing monitoring and management of potential long-term complications or adverse events from bispecific therapy.

Panelists discuss how community practices implement protocols and processes to monitor and manage potential long-term complications or adverse events associated with bispecific therapy, focusing on patient follow-up, adverse event reporting, and ongoing risk assessment.

Panelists discuss how cytokine release syndrome and neurological toxicities have been the most challenging adverse events to manage with GPRC5D-targeted therapies, requiring proactive monitoring and intervention strategies, while noting that these side effects are generally similar to those seen with other bispecifics.

Panelists discuss how cytokine release syndrome and neurological toxicities have been the most prevalent safety concerns in community settings when using bispecific therapies, requiring careful monitoring and management strategies.

Panelists discuss how GPRC5D-targeted bispecifics are likely to be incorporated earlier in treatment sequencing for multiple myeloma in the future, while considering factors such as optimal timing, potential combinations with other therapies, sequencing strategies, and possible drug interactions when integrating these treatments into the overall management of relapsed/refractory multiple myeloma patients.

Panelists discuss how specific biomarkers, such as GPRC5D expression levels, and clinical features, influence their decision to initiate GPRC5D bispecific therapies in multiple myeloma patients.

Panelists discuss how patient selection for GPRC5D-targeted therapies in the relapsed/refractory setting is guided by factors such as prior treatment history, including the number and types of previous therapies, with special consideration given to patients who have exhausted other options or shown resistance to earlier lines of treatment.

Panelists discuss how certain patient subgroups, such as those with high-risk cytogenetics or extramedullary disease, may experience different outcomes with GPRC5D bispecific therapies, though more data is needed to draw definitive conclusions about subgroup-specific responses.

Panelists discuss how GPRC5D bispecific therapies have shown promising efficacy in real-world relapsed/refractory multiple myeloma patients.

Panelists discuss how their clinical experience with GPRC5D bispecific therapies has been limited or nonexistent due to the novelty of these treatments in multiple myeloma.